Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TECH
stocks logo

TECH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
290.15M
-2.32%
0.434
+3.3%
321.53M
+1.69%
0.565
+0.84%
326.25M
+2.93%
0.560
+5.71%
Estimates Revision
The market is revising Downward the revenue expectations for Bio-Techne Corporation (TECH) for FY2026, with the revenue forecasts being adjusted by -1.47% over the past three months. During the same period, the stock price has changed by 16.78%.
Revenue Estimates for FY2026
Revise Downward
down Image
-1.47%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-1.83%
In Past 3 Month
Stock Price
Go Up
up Image
+16.78%
In Past 3 Month
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 67.50 USD with a low forecast of 60.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 67.50 USD with a low forecast of 60.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 63.540
sliders
Low
60.00
Averages
67.50
High
73.00
Current: 63.540
sliders
Low
60.00
Averages
67.50
High
73.00
Baird
Catherine Ramsey Schulte
Neutral
downgrade
$62 -> $61
2025-11-06
Reason
Baird
Catherine Ramsey Schulte
Price Target
$62 -> $61
2025-11-06
downgrade
Neutral
Reason
Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Bio-Techne to $61 from $62 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
UBS
Buy
maintain
$65 -> $70
2025-11-06
Reason
UBS
Price Target
$65 -> $70
2025-11-06
maintain
Buy
Reason
UBS raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares.
Evercore ISI
Outperform
to
NULL
downgrade
$72 -> $68
2025-11-06
Reason
Evercore ISI
Price Target
$72 -> $68
2025-11-06
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Bio-Techne to $68 from $72 and keeps an Outperform rating on the shares. The firm said it is trimming expectations for organic growth due to timing issue with cell therapy customers, yet the macro recovery thesis remains intact.
TD Cowen
Kyle Boucher
Buy
maintain
$65 -> $70
2025-10-14
Reason
TD Cowen
Kyle Boucher
Price Target
$65 -> $70
2025-10-14
maintain
Buy
Reason
TD Cowen analyst Kyle Boucher raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares. The firm noted consensus estimates have moved lower since F4Q earnings, and while they lowered their estimates for 1H2026 given difficult year-over-year comparisons, they maintain their positive view on shares.
RBC Capital
Sector Perform -> Outperform
upgrade
$73
2025-09-02
Reason
RBC Capital
Price Target
$73
2025-09-02
upgrade
Sector Perform -> Outperform
Reason
RBC Capital upgraded Bio-Techne to Outperform from Sector Perform with a $73 price target.
RBC Capital
Conor McNamara
Sector Perform -> Outperform
upgrade
$61 -> $73
2025-09-02
Reason
RBC Capital
Conor McNamara
Price Target
$61 -> $73
2025-09-02
upgrade
Sector Perform -> Outperform
Reason
As previously reported, RBC Capital analyst Conor McNamara upgraded Bio-Techne to Outperform from Sector Perform with a price target of $73, up from $61. The firm expects a return to mid-to-high-single digit growth in the next 12 months to drive multiple expansion that better reflects Bio-Techne's ability to consistently grow revenue faster than larger Integrator peers, the analyst tells investors. In addition, exposure to high growth areas - like bioprocessing and regenerative medicine - should continue to fuel growth expectations over the next 12 months, the analyst says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bio-Techne Corp (TECH.O) is 31.51, compared to its 5-year average forward P/E of 42.13. For a more detailed relative valuation and DCF analysis to assess Bio-Techne Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
42.13
Current PE
31.51
Overvalued PE
52.94
Undervalued PE
31.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
29.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
36.74
Undervalued EV/EBITDA
22.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.14
Current PS
0.00
Overvalued PS
14.38
Undervalued PS
7.90
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 2911.08% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 5004.01% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2911.08% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TECH News & Events

Events Timeline

(ET)
2025-11-18
07:20:23
Bio-Techne Signs Licensing Deal with Monod Bio
select
2025-11-05 (ET)
2025-11-05
06:54:02
Bio-Techne announces Q1 adjusted EPS of 42 cents, matching consensus expectations.
select
2025-11-04 (ET)
2025-11-04
09:48:17
Bio-Techne and Nucleai Share Findings from SECOMBIT Clinical Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-25PRnewswire
Bio-Techne to Present at Upcoming Investor Conferences

  • Upcoming Investor Conferences: Bio-Techne Corporation will present at three investor conferences in December 2025, including the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and the Nasdaq Investor Conference.

  • Live Webcast Availability: Presentations from these conferences will be accessible via a live webcast on Bio-Techne's Investor Relations website.

  • Company Overview: Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating over $1.2 billion in net sales in fiscal 2025.

  • Employee and Product Information: The company has approximately 3,100 employees and offers a portfolio of hundreds of thousands of products to assist in scientific investigations and clinical testing.

[object Object]
Preview
8.0
11-21NASDAQ.COM
Options Trading for Bio-Techne (TECH) in the First Week of July 2026

  • Put Contract Overview: The $55.00 put contract has a bid of $4.40, allowing investors to buy shares at a cost basis of $50.60, which is an 8% discount from the current price of $59.67. There is a 67% chance the contract may expire worthless, offering an 8% return on cash commitment.

  • Call Contract Overview: The $65.00 call contract has a bid of $5.20, enabling investors to sell shares at that price, potentially yielding a total return of 17.65% if exercised. The contract is out-of-the-money by 9%, with a 50% chance of expiring worthless, which would provide an 8.71% additional return.

  • Volatility Insights: The implied volatility for the put contract is 50%, while the call contract has an implied volatility of 47%. The actual trailing twelve-month volatility is calculated at 43%.

  • YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 12.27% annualized return if it expires worthless, and the call offering a 13.37% annualized return under similar conditions.

[object Object]
Preview
7.5
11-18Newsfilter
Bio-Techne Acquires AI-Developed NovoBody™ Duo Molecules from Monod Bio to Enhance Recombinant Protein Offerings

  • Partnership Announcement: Bio-Techne has entered a licensing agreement with Monod Bio to gain exclusive commercial rights to NovoBody™ Duo molecules, which are AI-designed bispecific binding proteins aimed at enhancing research and diagnostics.

  • Innovation in Protein Design: The NovoBody™ Duo molecules offer advanced customization and performance, allowing for rapid and cost-effective engineering compared to traditional antibodies, thus facilitating next-generation research tools.

  • Strategic Alignment: This collaboration aligns with Bio-Techne's strategic growth initiatives and supports advancements in precision medicine, reinforcing its leadership in AI-enabled innovation within the life sciences sector.

  • Company Backgrounds: Bio-Techne is a global provider of life science tools and reagents, while Monod Bio specializes in AI-powered protein design, focusing on creating novel protein binders for research and diagnostic applications.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bio-Techne Corp (TECH) stock price today?

The current price of TECH is 63.54 USD — it has decreased -0.44 % in the last trading day.

arrow icon

What is Bio-Techne Corp (TECH)'s business?

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

arrow icon

What is the price predicton of TECH Stock?

Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 67.50 USD with a low forecast of 60.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bio-Techne Corp (TECH)'s revenue for the last quarter?

Bio-Techne Corp revenue for the last quarter amounts to 286.56M USD, decreased -1.00 % YoY.

arrow icon

What is Bio-Techne Corp (TECH)'s earnings per share (EPS) for the last quarter?

Bio-Techne Corp. EPS for the last quarter amounts to 0.24 USD, increased 14.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bio-Techne Corp (TECH)'s fundamentals?

The market is revising Downward the revenue expectations for Bio-Techne Corporation (TECH) for FY2026, with the revenue forecasts being adjusted by -1.47% over the past three months. During the same period, the stock price has changed by 16.78%.
arrow icon

How many employees does Bio-Techne Corp (TECH). have?

Bio-Techne Corp (TECH) has 3100 emplpoyees as of December 05 2025.

arrow icon

What is Bio-Techne Corp (TECH) market cap?

Today TECH has the market capitalization of 9.90B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free